Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Livent has reported for 9 months of 2023

11/1/23 LTHM

First Solar has reported for 9 months of 2023

11/1/23 FSLR

HeadHunter is ready to buy back its shares for 20% of the market value

11/1/23 HEAD

Yandex has rewritten part of its assets in Russia to Technoyak LLC

10/31/23 YNDX

Aeroflot reported for 9 months of 2023 by RAS

10/31/23 AFLT

Pharmsintez reported for 9 months of 2023 by RAS

10/31/23 LIFE

TMK will supply complexes for laser-hybrid welding of pipes

10/31/23 TRMK

Abrau-Durso has a new CEO

10/31/23 ABRD

Rosseti Center reported for 9 months of 2023 by RAS

10/31/23 MRKC

Rosseti Center and Volga Region reported for 9 months of 2023 by RAS

10/31/23 MRKP